ATE229073T1 - Protein e25a, methoden zu dessen herstellung und anwendung - Google Patents

Protein e25a, methoden zu dessen herstellung und anwendung

Info

Publication number
ATE229073T1
ATE229073T1 AT97939804T AT97939804T ATE229073T1 AT E229073 T1 ATE229073 T1 AT E229073T1 AT 97939804 T AT97939804 T AT 97939804T AT 97939804 T AT97939804 T AT 97939804T AT E229073 T1 ATE229073 T1 AT E229073T1
Authority
AT
Austria
Prior art keywords
protein
cancer
nucleic acid
refractory prostate
hormone refractory
Prior art date
Application number
AT97939804T
Other languages
English (en)
Inventor
Robert E Reiter
Owen N Witte
Charles L Sawyers
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of ATE229073T1 publication Critical patent/ATE229073T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT97939804T 1996-09-06 1997-09-05 Protein e25a, methoden zu dessen herstellung und anwendung ATE229073T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2556996P 1996-09-06 1996-09-06
PCT/US1997/015606 WO1998010069A2 (en) 1996-09-06 1997-09-05 E25a PROTEIN, METHODS FOR PRODUCTION AND USE THEREOF

Publications (1)

Publication Number Publication Date
ATE229073T1 true ATE229073T1 (de) 2002-12-15

Family

ID=21826823

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97939804T ATE229073T1 (de) 1996-09-06 1997-09-05 Protein e25a, methoden zu dessen herstellung und anwendung

Country Status (7)

Country Link
US (2) US6093800A (de)
EP (1) EP0942972B1 (de)
AT (1) ATE229073T1 (de)
AU (1) AU4181897A (de)
CA (1) CA2265889A1 (de)
DE (1) DE69717664D1 (de)
WO (1) WO1998010069A2 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4776075B2 (ja) * 1998-12-31 2011-09-21 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 改変ｈｉｖｅｎｖポリペプチド
AU2487300A (en) 1998-12-31 2000-07-31 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US7935805B1 (en) * 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
CA2360347C (en) * 1998-12-31 2013-05-07 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
DE60044879D1 (de) 1999-10-28 2010-10-07 Agensys Inc 36p6d5: ausgeschiedenes tumorprotein
WO2002043575A2 (en) * 2000-12-01 2002-06-06 Duke University Zinc alpha-2-glycoprotein as indicator of cancer
WO2002057417A2 (en) * 2000-12-15 2002-07-25 Origene Technologies, Inc. Angiogenesis gene and modulators
CA2443147A1 (en) * 2001-04-10 2002-10-24 Agensys, Inc. Nucleic acid and corresponding protein entitled 184p1e2 useful in treatment and detection of cancer
WO2003004657A1 (en) * 2001-07-05 2003-01-16 Chiron Corporation Polynucleotides encoding antigenic hiv type b and/or type c polypeptides, polypeptides and uses thereof
AU2002320314A1 (en) 2001-07-05 2003-01-21 Chiron, Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
WO2003020876A2 (en) * 2001-08-31 2003-03-13 Chiron Corporation Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides and uses thereof
US20030170614A1 (en) * 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
WO2004020999A1 (en) * 2002-08-30 2004-03-11 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
US8507445B2 (en) * 2001-09-07 2013-08-13 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
US7671010B2 (en) * 2002-08-30 2010-03-02 The Board Of Regents Of The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
HUE036180T2 (hu) 2006-09-26 2018-06-28 Infectious Disease Res Inst Szintetikus adjuvánst tartalmazó vakcina készítmény
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US20100129361A1 (en) * 2007-05-01 2010-05-27 The Brigham And Women's Hospital Immunosuppression with antibody against itm2a
HUE031051T2 (en) * 2009-06-05 2017-06-28 Infectious Disease Res Inst Synthetic glycopyranosyl lipid adjuvant and vaccine compositions containing it
EP3632463A1 (de) 2011-04-08 2020-04-08 Immune Design Corp. Immunogene zusammensetzungen und verfahren zur verwendung der zusammensetzungen zur induzierung humoraler und zellulärer immunreaktionen
WO2013119856A1 (en) 2012-02-07 2013-08-15 Infectious Disease Research Institute Improved adjuvant formulations comprising tlr4 agonists and methods of using the same
SI2850431T1 (en) 2012-05-16 2018-08-31 Immune Design Corp. Vaccines for hsv-2
EP2986303B1 (de) 2013-04-18 2020-02-26 Immune Design Corp. Gla-monotherapie zur verwendung in der krebsbehandlung
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
IL246456B2 (en) 2013-12-31 2024-06-01 Access To Advanced Health Inst Formulations will be assembled into a single vial
CA3023271A1 (en) 2016-06-01 2017-12-07 Infectious Disease Research Institute Nanoalum particles containing a sizing agent
CA3078223A1 (en) 2017-09-08 2019-03-14 Infectious Disease Research Institute Liposomal formulations comprising saponin and methods of use
WO2020243115A1 (en) 2019-05-25 2020-12-03 Infectious Disease Research Institute Composition and method for spray drying an adjuvant vaccine emulsion

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4204642B2 (ja) * 1992-11-05 2009-01-07 スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ 前立腺に特異的な膜抗原

Also Published As

Publication number Publication date
AU4181897A (en) 1998-03-26
US7030232B1 (en) 2006-04-18
WO1998010069A2 (en) 1998-03-12
EP0942972A2 (de) 1999-09-22
WO1998010069A3 (en) 1998-05-07
EP0942972B1 (de) 2002-12-04
DE69717664D1 (de) 2003-01-16
CA2265889A1 (en) 1998-03-12
US6093800A (en) 2000-07-25

Similar Documents

Publication Publication Date Title
ATE229073T1 (de) Protein e25a, methoden zu dessen herstellung und anwendung
ES2317704T3 (es) Un nuevo metodo para el diagnostico, seguimiento, estadificacion. imagineria y tratamiento de distintos canceres.
DE69926630D1 (de) Antikörper gegen die ed-b domäne von fibronektin, solche antikörper enthaltende konjugate, und deren verwendung zur diagnose und therapie von angiogenese-assoziierten tumoren und krankheiten
DE60134178D1 (de) Trp8 krebsmarker
ATE345399T1 (de) Biomarker und targets für die diagnose, prognose und behandlung von prostat krankheiten
WO2004110345A3 (en) Differentially expressed genes involved in cancer, the polypeptides encoded thereby, and methods of using the same
MXPA02011656A (es) Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
DE69837529D1 (de) Proteinmarker für lungenkrebs und deren verwendung
WO2004092338A3 (en) Compositions, splice variants and methods relating to cancer specific genes and proteins
DE60028830D1 (de) Anti-april antikörper und hybridomazellen
PT991421E (pt) Deteccao e modulacao das iap e naip para o diagnostico e tratamento de doenca proliferativa
AU2001253079A1 (en) Methods, compositions and kits for the detection and monitoring of breast cancer
NZ513498A (en) Monoclonal antibodies, antigens and diagnosis and therapy of malignant diseases
BR0315666A (pt) Dna de a34 e a33 do tipo 3, proteìnas, seus anticorpos e métodos de tratamento usando os mesmos
AR026946A1 (es) Osteoprotegerina/receptores de factores de necrosis de tumores
WO2002031209A3 (en) Genes related to development of refractory prostate cancer
DE60032784D1 (de) Markerproteine für prostatakrebs
WO2003105773A3 (en) Activating mutations of platelet derived growth factor receptor alpha (pdgfra) as diagnostic markers and therapeutic targets:
EP1377596A4 (de) Ttk in der diagnose und als therapeutisches target bei krebs
DE69126038D1 (de) Diagnose von krebs-metastasen durch das mts-1 gen
DE60044350D1 (de) Prostata-spezifisches gen pcgem1 und methoden zu dessen verwendung zur erkennung, behandlung und prävention von prostatakrebs
AP2000001917A0 (en) Gene encoding labyrinthin, a marker for cancer.
ATE277352T1 (de) Einetenascin-c isoform als marker für neoplasmen
DE60221115D1 (de) Zusammensetzungen und verfahren zur verwendung von fibronektin-fragmenten bei krebsdiagnose
WO2004040312A3 (fr) Proceded de dosage du ngf pour le diagnostic in vitro du cancer du sein et utilisation en therapie

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties